Protocol Ledger

NCT05638776 · Phase II · COMPLETED

Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Diffusion Capacity Defect by REGEND001 Cell Therapy

Interventional Phase II clinical trial protocol NCT05638776 sponsored by Regend Therapeutics in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-12-06 Enrollment: 58 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05638776
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)58 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05638776
Protocol FieldVerified Registry Value
NCT IdentifierNCT05638776
Consolidated Lead SponsorRegend Therapeutics
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment58 participants (ACTUAL)
Registered Start Date2022-12-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI